The Potential Role of an Anti-HBs Antibody in Combination Therapy to Achieve Functional Cure in Chronic HBV

Time: 11:30 am
day: Day One


• Discuss how combination therapy is likely needed to achieve functional cure of chronic HBV by suppressing the virus and stimulating/enhancing the immune system

• Evaluate how VIR-3434 is an HBV-neutralizing monoclonal antibody with multiple potential mechanisms of action including cross-presentation and stimulation of T cells (vaccinal effect)

• Review in vitro, in vivo and clinical data on VIR-3434 and the vaccinal effect of antibodies and how it may play a role in combination therapy